Hula, a Physical Activity Intervention for Female-Cancer Survivors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- University of Hawaii Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Lives on Oahu
- Diagnosed with primary breast,cervical, endometrial or ovarian cancer (stage I-III)
- Completed initial regional and systemic treatment for breast cancer 2 months ago
- Physically capable of doing the hula-based physical activity
- Receives approval by attending physician to participate in trial
Exclusion Criteria:
- Currently undergoing chemotherapy or radiation therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Hula
Hula is an ancient, Native Hawaiian dance form of cultural expression and physical activity.
Participants will attend one-hour hula classes twice a week for six months.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hula Program Feasibility (Compliance as measured by the proportion of total sessions attended and a questionnaire regarding satisfaction with the program at the end of the intervention)
Time Frame: 6 months after the start of the intervention program
|
Compliance as measured by the proportion of total sessions attended and a questionnaire regarding satisfaction with the program at the end of the intervention
|
6 months after the start of the intervention program
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biomarkers - Sex Hormones (Circulating levels of sex hormones measured in serum samples)
Time Frame: Baseline, 6 months and 12 months after the start of the intervention program
|
Circulating levels of sex hormones measured in serum samples.
|
Baseline, 6 months and 12 months after the start of the intervention program
|
|
Biomarkers - Cytokines (Circulating levels of cytokines measured in serum samples.)
Time Frame: Baseline, 6 months and 12 months after the start of the intervention program
|
Circulating levels of cytokines measured in serum samples.
|
Baseline, 6 months and 12 months after the start of the intervention program
|
|
Biomarkers - Inflammatory Markers (Circulating levels of leptin, CRP, IGF-1, and IGFBP3 measured in serum samples collectively.)
Time Frame: Baseline, 6 months and 12 months after the start of the intervention program
|
Circulating levels of leptin, CRP, IGF-1, and IGFBP3 measured in serum samples collectively.
|
Baseline, 6 months and 12 months after the start of the intervention program
|
|
DNA Methylation Patterns (DNA methylation patterns as detected with the Illumina Assay containing methylation sites in RefSeq genes and CpG islands collectively.)
Time Frame: Baseline, 6 months and 12 months after the start of the intervention program
|
DNA methylation patterns as detected with the Illumina Assay containing methylation sites in RefSeq genes and CpG islands collectively.
|
Baseline, 6 months and 12 months after the start of the intervention program
|
|
Self-Report Outcomes - Demographics (Collectively looking at demographic items as measured on the baseline questionnaire, including ethnicity, education, family, history of cancer, stage of cancer, treatment type, and comorbidities.)
Time Frame: Baseline, 6 months and 12 months after the start of the intervention program
|
Collectively looking at demographic items as measured on the baseline questionnaire, including ethnicity, education, family, history of cancer, stage of cancer, treatment type, and comorbidities.
|
Baseline, 6 months and 12 months after the start of the intervention program
|
|
Self-Report Outcomes - Physical Activity (Minutes per week of exercise assessed using The Women's Health Initiative Physical Activity Questionnaire)
Time Frame: Baseline, 6 months and 12 months after the start of the intervention program
|
Minutes per week of exercise assessed using The Women's Health Initiative Physical Activity Questionnaire
|
Baseline, 6 months and 12 months after the start of the intervention program
|
|
Self-Report Outcomes - Health-Related Quality of Life (Quality of life of participants assessed using The European Organization for Research and Treatment of Cancer QLQ-C30.)
Time Frame: Baseline, 6 months and 12 months after the start of the intervention program
|
Baseline, 6 months and 12 months after the start of the intervention program
|
|
|
Self-Report Outcomes - Fatigue (assessed using The Brief Fatigue Inventory (BFI)
Time Frame: Baseline, 6 months and 12 months after the start of the intervention program
|
The severity and impact of fatigue on daily functioning assessed using The Brief Fatigue Inventory (BFI).
|
Baseline, 6 months and 12 months after the start of the intervention program
|
|
Self-Report Outcomes - Depression (indicated using The Centers for Epidemiological Studies Depression Scale (CES-ED)
Time Frame: Baseline, 6 months and 12 months after the start of the intervention program
|
The presence of depression as indicated using The Centers for Epidemiological Studies Depression Scale (CES-ED).
|
Baseline, 6 months and 12 months after the start of the intervention program
|
|
Self-Report Outcomes - Affective States (assessed using The Profile of Mood States short form (POMS-SF) questionnaire.)
Time Frame: Baseline, 6 months and 12 months after the start of the intervention program
|
Affect of participants assessed using The Profile of Mood States short form (POMS-SF) questionnaire.
|
Baseline, 6 months and 12 months after the start of the intervention program
|
|
Self-Report Outcomes - Social Constraints (assessed using The 10-item Social Constraints Scale.)
Time Frame: Baseline, 6 months and 12 months after the start of the intervention program
|
How people adjust and cope with a cancer diagnosis assessed using The 10-item Social Constraints Scale.
|
Baseline, 6 months and 12 months after the start of the intervention program
|
|
Self-Report Outcomes - Cognitive Functioning (assessed using the 42-item FACTcog
Time Frame: Baseline, 6 months and 12 months after the start of the intervention program
|
2 subscales assess cognitive deficiency and cognitive capability
|
Baseline, 6 months and 12 months after the start of the intervention program
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Erin Bantum, MA, PhD, University of Hawaii Cancer Research Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Uterine Cervical Neoplasms
- Ovarian Neoplasms
- Endometrial Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- Bantum-2013-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.